路易体痴呆的诊断及其他生物标志物:从研究到临床实践
本文综述路易体痴呆的临床特征异质性和常见误诊问题,指出其他脑共病限制部分诊断标志物的效用。新型神经影像技术对脑组织成分和微结构高度敏感,液体标志物可检测极低浓度神经病理蛋白,这些标志物有望用于临床实践和临床试验结局指标,促进早期诊断、疾病监测和预后评估。
要点
- 路易体痴呆临床特征包括视幻觉、认知波动、帕金森综合征和快速眼动睡眠行为障碍。
- 该病表现和进展异质,误诊常见,其他脑共病频繁限制部分诊断标志物效用。
- 新型神经影像和液体标志物有望用于临床实践和临床试验结局指标。
核心结论
- 新型神经影像和液体生物标志物有望用于路易体痴呆的早期诊断、疾病监测和预后评估,并促进疾病修饰试验的实施。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 路易体痴呆临床以视幻觉、认知波动、帕金森综合征和快速眼动睡眠行为障碍为特征,可导致比其他痴呆更多的衰弱。
- 该病表现和进展异质,误诊常见,其他脑共病频繁,限制了部分诊断标志物的效用。
- 诊断和预后标志物稀缺,阻碍了治疗试验的实施。
- 新型神经影像技术对脑组织成分和微结构具有高敏感性。
- 液体标志物正在开发,用于检测极低浓度的神经病理蛋白。
临床怎么用
- 这些生物标志物可能很快被临床实践采用,并作为临床试验的结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dementia with Lewy bodies is characterised clinically by visual hallucinations, fluctuating cognitive function, parkinsonism, and rapid eye movement sleep behaviour disorder, and can cause more frailty than other dementias. The disease is heterogeneous in presentation and progression, and misdiagnoses are common. In people with dementia with Lewy bodies, other brain copathologies are frequent, limiting the usefulness of some diagnostic biomarkers. This heterogeneity, together with the scarcity of diagnostic and prognostic biomarkers, has hindered the implementation of therapeutic trials. However, novel neuroimaging techniques have emerged with high sensitivity to brain tissue composition and microstructure. Fluid biomarkers are being developed to detect very low concentrations of neuropathological proteins. These biomarkers could soon be adopted in clinical practice and incorporated as outcome measures in clinical trials. These advances will pave the way for early diagnosis, disease monitoring, and prognosis, and will facilitate the implementation of disease-modifying trials.
引用
- Zarkali A, Bartl M, Fox NC, et al. Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings. Lancet Neurol. 2025. PMID: 41240920. doi:10.1016/S1474-4422(25)00314-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。